RT Journal Article
SR Electronic
T1 Metabolic Dysfunction Related Liver Disease as a Risk Factor for Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.19.21264255
DO 10.1101/2021.10.19.21264255
A1 Taylor, Alasdair
A1 Siddiqui, Moneeza K
A1 Ambery, Philip
A1 Armisen, Javier
A1 Challis, Benjamin G.
A1 Haefliger, Carolina
A1 Pearson, Ewan R.
A1 Doney, Alex S.F.
A1 Dillon, John F.
A1 Palmer, Colin N.A.
YR 2021
UL http://medrxiv.org/content/early/2021/10/20/2021.10.19.21264255.abstract
AB The aim of this study was to investigate the association with obesity, diabetes and related liver dysfunction and the incidence of cancer.This study was conducted with health record data available from the National Health Service in Tayside and Fife. GoDARTS, SHARE and Tayside and Fife diabetics, three Scottish cohorts of 13,695, 62,438, and 16,312 patients respectively were analysed in this study. Participants in GoDARTS were a volunteer sample, with half having T2DM. SHARE were a volunteer sample. Tayside and Fife diabetics was a population level cohort. Metabolic dysfunction-related liver disease (MDLD) was defined using ALT measurements, and individuals with alternative causes of liver disease (alcohol abuse, viruses etc) were excluded from the analysis. Other indicators of liver disease were analysed including the Fatty Liver Index, Fibrosis Score(FIB-4) and hospital admissions for NASH. The main outcomes were cancer incidence and cancer death.MDLD associated with increased cancer incidence with a hazard ratio of 1.31 in a cox proportional hazards model adjusted for sex, type 2 diabetes, BMI, and smoking status (95% CI = 1.27 – 1.35, p < 0.0001). This was replicated in two further cohorts, and similar associations with cancer incidence were found for Fatty Liver Index (FLI), FIB-4 and NASH. Homozygous carriers of the common NAFLD risk variant PNPLA3 rs738409 had increased risk of cancer. (HR = 1.27 (1.02-1.58), p = 3.1×10−2). BMI was not independently associated with cancer incidence when MDLD was included as a covariate. MDLD was associated with increased risk of cancer death (HR = 1.40, 95% CI =1.33 - 1.47, p < 0.0001).MDLD, FLI, FIB-4 and NASH associated with increased risk of cancer incidence and death. Further, we found evidence of a causal association between NAFLD and cancer using the established causal risk allele of PNPLA3 as a genetic instrument. NAFLD may be a major component of the relationship between obesity and cancer incidence.Lay Summary We found that individuals with metabolic dysfunction-related liver disease (MDLD) have higher overall cancer risk than healthy individuals, as well as increased risk of specific cancers such as colon, breast and lung. We also show that when MDLD is accounted for, obesity does not significantly increase overall cancer risk.Competing Interest StatementPhilip Ambery, Javier Armisen, Benjamin Challis and Carolina Haefliger are employees of AstraZeneca and are shareholders of AstraZeneca.Funding StatementThis study was funded by AstraZeneca through Stratified Medicine Scotland Innovation centre. The funders had a role in the design and conduct of the study; analysis, interpretation of the data, preparation, review, and approval of the manuscript for publication. The corresponding author had full access to all the data and final responsibility for submission. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We are grateful to all the participants in this study, the general practitioners, the Scottish School of Primary Care for their help in recruiting the participants and to the whole team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The study complies with the Declaration of Helsinki. We acknowledge the support of the Health Informatics Centre, University of Dundee, for managing and supplying the anonymized data and NHS Tayside, the original data owner. The NHS provided ethical approval for access to the anonymised data. Dissemination of the results of this study to participants was not applicable. We acknowledge the support of the NIHR for data acquisition. SHARE has ongoing funding from NHS Research Scotland and established by funding fromThe Wellcome Trust Biomedical Resource GrantNo. 099177/Z/12/Z. The Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection (GoDARTS) was funded by The Wellcome Trust (072960/Z/03/Z, 084726/Z/08/Z, 084727/Z/08/Z, 085475/Z/08/Z, 085475/B/08/Z) and as part of the EU IMI-SUMMIT program.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData analysed in this manuscript is not publicly available.